These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29361501)

  • 1. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
    Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
    EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport.
    Yuan W; Yu B; Yu M; Kuai R; Morin EE; Wang H; Hu D; Zhang J; Moon JJ; Chen YE; Guo Y; Schwendeman A
    J Control Release; 2021 Jan; 329():361-371. PubMed ID: 33188828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
    Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
    Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
    Breevoort SR; Angdisen J; Schulman IG
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
    Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development.
    van der Stoep M; Li Z; Calpe-Berdiel L; van der Sluis RJ; Saleh P; McKinnon HJ; Smit MJ; Korporaal SJ; Van Berkel TJ; Van Eck M; Hoekstra M
    Biochem Pharmacol; 2013 Dec; 86(11):1594-602. PubMed ID: 24095721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice.
    Dai XY; Ou X; Hao XR; Cao DL; Tang YL; Hu YW; Li XX; Tang CK
    J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.
    Verschuren L; de Vries-van der Weij J; Zadelaar S; Kleemann R; Kooistra T
    J Lipid Res; 2009 Feb; 50(2):301-11. PubMed ID: 18757914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
    Ou X; Dai X; Long Z; Tang Y; Cao D; Hao X; Hu Y; Li X; Tang C
    Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo.
    Beyer TP; Schmidt RJ; Foxworthy P; Zhang Y; Dai J; Bensch WR; Kauffman RF; Gao H; Ryan TP; Jiang XC; Karathanasis SK; Eacho PI; Cao G
    J Pharmacol Exp Ther; 2004 Jun; 309(3):861-8. PubMed ID: 14960661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE(-/-) mice.
    Chen J; Zhao L; Sun D; Narsinh K; Li C; Zhang Z; Qi S; Wei G; Li W; Guo W; Cao F
    Inflamm Res; 2012 Dec; 61(12):1299-307. PubMed ID: 22833121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine accelerates atherosclerosis via inhibiting LXRα-mediated ABCA1/ABCG1-dependent cholesterol efflux from macrophages.
    Jin P; Bian Y; Wang K; Cong G; Yan R; Sha Y; Ma X; Zhou J; Yuan Z; Jia S
    Life Sci; 2018 Dec; 214():41-50. PubMed ID: 30393020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis.
    Zhang XQ; Even-Or O; Xu X; van Rosmalen M; Lim L; Gadde S; Farokhzad OC; Fisher EA
    Adv Healthc Mater; 2015 Jan; 4(2):228-36. PubMed ID: 25156796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.
    Gui Y; Yao S; Yan H; Hu L; Yu C; Gao F; Xi C; Li H; Ye Y; Wang Y
    Cardiovasc Res; 2016 Oct; 112(1):502-14. PubMed ID: 27460841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism.
    Kaseda R; Tsuchida Y; Yang HC; Yancey PG; Zhong J; Tao H; Bian A; Fogo AB; Linton MRF; Fazio S; Ikizler TA; Kon V
    BMC Nephrol; 2018 Jan; 19(1):17. PubMed ID: 29374468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144.
    Ramírez CM; Rotllan N; Vlassov AV; Dávalos A; Li M; Goedeke L; Aranda JF; Cirera-Salinas D; Araldi E; Salerno A; Wanschel A; Zavadil J; Castrillo A; Kim J; Suárez Y; Fernández-Hernando C
    Circ Res; 2013 Jun; 112(12):1592-601. PubMed ID: 23519695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospholipid transfer protein is regulated by liver X receptors in vivo.
    Cao G; Beyer TP; Yang XP; Schmidt RJ; Zhang Y; Bensch WR; Kauffman RF; Gao H; Ryan TP; Liang Y; Eacho PI; Jiang XC
    J Biol Chem; 2002 Oct; 277(42):39561-5. PubMed ID: 12177004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.